1. Ahmad, M., Hirz, M., Pichler, H., & Schwab, H. (2014). Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Applid Microbiology and Biotechnology, 98, 5301e17. DOI: [DOI:10.1007/s00253-014-5732-5]

2. Ali Khan, T., Mazhar, H., Saleha, S., Nawaz Tipu, H., Muhammad, N., & Nasser Abbas, M. (2016). Interferon-gamma improves macrophages function against M. tuberculosis in multidrug-resistant tuberculosis patients. Chemotherapy Research and Practice, 2016. 7295390. https://dx.doi.org/10.1155/2016/7295390 [DOI:10.1155/2016/7295390]

3. Arbabi, M., Alasti, F., Sanati, M.H., Hosseini, S., Deldar, A., & Maghsoudi, N. (2003). Cloning and expression of human gamma-interferon cDNA in E. coli. Iranian Journal of Biotechnology, 1(2), 87-94.

4. Arellano, G., Ottum, P.A., Reyes, L.I., Burgos, P.I., & Naves, R. (2015). Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis. Frontiers in Immunology, 6, 492. DOI: [DOI:10.3389/fimmu.2015.00492]

5. Armstrong-James, D., Teo, I.A., Shrivastava, S., Petrou, M.A., Taube, D., Dorling, A., et al. (2010). Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. American Journal of Transplantation, 10(8), 1796-1803. DOI: https://doi. 10.1111/j.1600-6143.2010.03094.x [DOI:10.1111/j.1600-6143.2010.03094.x]

6. Bagheri, K., Jalali Javaran, M., Mahboudi, F., Moeini, A., & Zebarjadi, A.R. (2010). Expression of human interferon gamma in Brassica napus seeds. African Journal of Biotechnology, 9(32), 5066-5072.

7. Bagis, H., Aktoprakligil, D., Gunes, C., Arat, S., Akkoc, T., Cetinkaya, G., et al. (2011). Expression of biologically active human interferon gamma in the milk of transgenic mice under the control of the murine whey acidic protein gene promoter. Biochemical Genetics, 49, 251-257. DOI: [DOI:10.1007/s10528-010-9403-7]

8. Bahonar, S., Palizban, F., & Montazeri, H. (2022). Expression profile of tumor educated platelets as biomarkers for diagnosis and early detection of cancer. Genetic Engineering and Biosafety Journal, 11(1), 54-63. URL: http://gebsj.ir/article-1-412-fa.html

9. Blin-Wakkach, C., Wakkach, A., Sexton, P.M., Rochet, N., & Carle, G.F. 2004. Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia, 18(9), 1505-151. DOI: [DOI:10.1038/sj.leu.2403449]

10. Bolko, L., Jiang, W., Tawara, N., Landon-Cardinal, O., Anquetil, C., Benveniste, O., et al. (2021). The role of interferons type I, II and III in myositis: a review. Brain Pathology, 31, e12955. DOI: [DOI:10.1111/bpa.12955]

11. Chen, J., Li, Y., Lai, F., Wang, Y., Sutter, K., Dittmer, U., et al. (2021). Functional comparison of interferon‐α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon‐α and interferon‐γ signaling. Hepatology, 73(2), 486-502. DOI: https://doi. 10.1002/hep.31282 [DOI:10.1002/hep.31282]

12. Chen, T.L., Lin, Y.L., Lee, Y.L., Yang, N.S., & Chan, M.T. (2004). Expression of bioactive human interferon gamma in transgenic rice cell suspension cultures. Transgenic Research, 13(5), 499-510. DOI: [DOI:10.1007/s11248-004-2376-8]

13. Chen, W.S., Villaflores, O.B., Jinn, T.R., Chan, M.T., Chang, Y.C., & Wu, T.Y. (2011). Expression of recombinant human interferon-gamma with antiviral activity in the bi-cistronic baculovirus-insect/larval system. Bioscience, Biotechnology and Biochemistry, 75(7), 1342-1348. DOI: [DOI:10.1271/bbb.110107]

14. Chung, B.K., Yusufi, F.N., Yang, Y., & Lee, D.Y. (2013). Enhanced expression of codon optimized interferon gamma in CHO cells. Journal of Biotechnology 167(3): 326-333. DOI: [DOI:10.1016/j.jbiotec.2013.07.011]

15. Condos, R., Rom, W.N., & Schluger, N.W. (1997). Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet, 349(9064), 1513-1515. DOI: [DOI:10.1016/S0140-6736(96)12273-X]

16. Cui, D., Huang, G., Yang, D., Huang, B., & An, B. (2013). Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 37(5), 507-513. DOI: [DOI:10.1016/j.clinre.2012.12.004]

17. Czarniecki, C.W., & Sonnenfeld, G. (2006). Clinical applications of interferon-gamma. In: Meager A (ed.) The interferons: characterization and application. Wiley-VCH Weinheim, 309-336. DOI: [DOI:10.1002/3527608206.ch11]

18. Davoudi, N., Hemmati, A., Khodayari, Z., Adeli, A., & Hemayatkar, M. (2011). Cloning and expression of human IFN- in Leishmania tarentolae. World Journal of Microbiology and Biotechnology, 27, 1893-1899. DOI: [DOI:10.1007/s11274-010-0648-4]

19. De Leede, L.G., Humphries, J.E., Bechet, A.C., Van Hoogdalem, E.J., & Spencer, D.G. (2008). Novel controlled release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. Journal of Interferon and Cytokine Research, 28(2), 113-122. DOI: [DOI:10.1089/jir.2007.0073]

20. Derynck, R., Singh, A., & Goeddel, D.V. (1983). Expression of the human interferon-gamma cDNA in yeast. Nucleic Acids Research, 11(6), 1819-1837. DOI: [DOI:10.1093/nar/11.6.1819]

21. Di Bisceglie, A.M., & Hoofnagle, J.H. (2002). Optimal therapy of hepatitis C. Hepatology 36(S1): S121-S127. DOI: [DOI:10.1002/hep.1840360716]

22. Dummer R. 2005. Emerging drugs in cutaneous T-cell lymphomas. Expert Opinion on Emerging Drugs, 10, 381-392. DOI: https://doi. 10.1517/14728214.10.2.381 [DOI:10.1517/14728214.10.2.381]

23. Dunn, G.P., Koebel, C.M., & Schreiber, R.D. (2006). Interferons, immunity and cancer immunoediting. Nature Reviews Immunology, 6(11), 836-848. DOI: [DOI:10.1038/nri1961]

24. Ebrahimi, N., Rajabi Memari, H., Ebrahimi, M.A., & Roayaei Ardakani, M. (2012). Cloning, transformation and expression of human gamma interferon gene in tomato (Lycopersicon Esculentum Mill.). Biotechnology and Biotechnological Equipment, 26(2), 2925-2929. DOI: [DOI:10.5504/BBEQ.2012.0004]

25. Edelbaum, O., Stein, D., Holland, N., Gafni, Y., Livneh, O., Novick, D., et al. (1992). Expression of active human interferon-beta in transgenic plants. Journal of Interferon and Cytokine Research, 12(6), 449-453. DOI: [DOI:10.1089/jir.1992.12.449]

26. Egelkrout, E., Rajan, V., & Howard, J.A. (2012). Overproduction of recombinant proteins in plants. Plant Science, 184, 83-101. DOI: [DOI:10.1016/j.plantsci.2011.12.005]

27. Filiz, S., Uygun, D.F.K., Sanal, Ö., Camcioğlu, Y., Somer, A., Barlan, I., et al. (2022). The demographic datas of chronic granulomatous disease patients and the comparation of the clinical datas before and after interferon-gamma treatment in our country. Asthma Allergy Immunology, 11(3), 153-161.

28. Fukuzawa, N., Tabayashi, N., Okinaka, Y., Furusawa, R., Furuta, K., Kagaya, U., et al. (2010). Production of biologically active Atlantic salmon interferon in transgenic potato and rice plants. Journal of Bioscience and Bioengineering, 110(2), 201-207. DOI: [DOI:10.1016/j.jbiosc.2010.02.005]

29. Grassegger, A., Schuler, G., Hessenberger, G., Walder‐Hantich, B., Jabkowski, J., MacHeiner, W., et al. (1998). Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. British Journal of Dermatology, 139(4), 639-648. DOI: [DOI:10.1046/j.1365-2133.1998.02460.x]

30. Gray, P.W., Leung, D.W., Pennica, D., Yelverton, E., Najarian, R., Simonsen, C.C., et al. (1982). Expression of human immune interferon cDNA in E. coli and monkey cells. Nature, 295(5849), 503-508. DOI: [DOI:10.1038/295503a0]

31. Gyurova, I.E., Ali, A., & Waggoner, S.N. (2020). Natural killer cell regulation of B cell responses in the context of viral infection. Viral Immunology, 33(4), 334-341. DOI: [DOI:10.1089/vim.2019.0129]

32. Hashioka, S., McGeer, E.G., Miyaoka, T., Wake, R., Horiguchi, J., & McGeer, P.L. (2015). Interferon-γ-induced neurotoxicity of human astrocytes. CNS & Neurological Disorders-Drug Targets, 14(2), 251-256. DOI: https://doi. 10.2174/1871527314666150217122305 [DOI:10.2174/1871527314666150217122305]

33. Haynes, J., & Weissman, C. (1983). Constitutive, long-term production of human interferons by hamster cells contalning multiple copies of a cloned interferon gene. Nucleic Acids Research, 11(3), 687-706. DOI: [DOI:10.1093/nar/11.3.687]

34. Heidari-Japelaghi, R., Haddad, R., Valizadeh, M., Dorani-Uliaie, E., & Jalali-Javaran, M. (2019a). Elastin-like polypeptide fusions for high-level expression and purification of human IFN-γ in Escherichia coli. Analytical Biochemistry, 585, 113401. DOI: [DOI:10.1016/j.ab.2019.113401]

35. Heidari-Japelaghi, R., Valizadeh, M., Haddad, R., Dorani-Uliaie, E., & Jalali-Javaran, M. (2020a). Fusion to elastin-like polypeptide increases production of bioactive human IFN-γ in tobacco. Transgenic Research, 29, 381-394. DOI: [DOI:10.1007/s11248-020-00205-y]

36. Heidari-Japelaghi, R., Valizadeh, M., Haddad, R., Dorani-Uliaie, E., & Jalali-Javaran, M. (2020b). Production of bioactive human IFN-γ protein by agroinfiltration in tobacco. Protein Expression and Purification, 173, 105616. DOI: [DOI:10.1016/j.pep.2020.105616]

37. Heidari-Japelaghi, R., Valizadeh, M., Haddad, R., Dorani-Uliaie, E., & Jalali-Javaran, M. (2019b). Elastin-like polypeptide fusions enhance transient expression of human IFN-γ in tobacco leaves. South African Journal of Botany, 125, 321-328. DOI: [DOI:10.1016/j.sajb.2019.08.003]

38. Hirata, T., & Kizuka, Y. (2021). N-glycosylation. In: Lauc G, Trbojević-Akmačić I (eds.) The role of glycosylation in health and disease. Advances in experimental medicine and biology. vol 1325, Springer, Cham.

39. Hu, Z.J., Xu, J., Yin, J.M., Li, L., Hou, W., Zhang, L.L., et al. (2020). Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients. Frontiers in immunology, 11, 585647. DOI: [DOI:10.3389/fimmu.2020.585647]

40. Huang, S.K., Jin, J.Y., Guan, Y.X., Yao, Z., Cao, K., & Yao, S.J. (2013). Refolding of recombinant human interferon gamma inclusion bodies in vitro assisted by colloidal thermo-sensitive poly(N-isopropylacrylamide) brushes grafted onto the surface of uniform polystyrene cores. Biochemical Engineering Journal, 74, 20-26. DOI: [DOI:10.1016/j.bej.2013.02.015]

41. Imel, E.A., Ziyue Liu, Z., Acton, D., Coffman, M., Gebregziabher, N., Tong, Y., et al. (2019). Interferon gamma‐1b does not increase markers of bone resorption in autosomal dominant osteopetrosis. Journal of Bone and Mineral Research, 34(8), 1436-1445. DOI: [DOI:10.1002/jbmr.3715]

42. Izu, A.E., Jaffe, H.S., Curnutte, J.T., & Ezekowitz, R.A.B. (2020). Interferon-gamma treatment of chronic granulomatous disease. In: Anti-infective applications of interferon-gamma. CRC Press, 11-28. [DOI:10.1201/9781003066903-2]

43. Jiang, M.C., Hu, C.C., Lin, N.S., & Hsu, Y.H. (2019). Production of human IFN-γ protein in Nicotiana benthamiana plant through an enhanced expression system based on bamboo mosaic virus. Viruses, 11(509), 1-18. DOI: [DOI:10.3390/v11060509]

44. Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020). Roles of IFN-γ in tumor progression and regression: a review. Biomarker Research, 8, 49. DOI: [DOI:10.1186/s40364-020-00228-x]

45. Key, L.L.Jr., Ries, W.L., Rodriguiz, R.M., & Hatcher, H.C. (1992). Recombinant human interferon gamma therapy for osteopetrosis. The Journal of Pediatrics, 121(1), 119-124. DOI: [DOI:10.1016/S0022-3476(05)82557-0]

46. Kim, D-Y., Han, D-K., Beak, H-J., Jung, S-T., Kook, H., & Hwang, Y-J. (2007). Long-term recombinant interferon-γ treatment in 2 cases of osteopetrosis. Korean Journal of Pediatrics, 50(11), 1129-1133. [DOI:10.3345/kjp.2007.50.11.1129]

47. Lagutin, O.V., Dobrovolsky, V.N., Vinogradova, T.V., Kyndiakov, B.N., Khodarovich, Y.M., Jenkins, N., et al. (1999). Efficient human IFN-gamma expression in the mammary gland of transgenic mice. Journal of Interferon and Cytokine Research, 19(2), 137-144. DOI: [DOI:10.1089/107999099314289]

48. Leister, P., Tileva, M., Krachmarova, E., & Nacheva, G. (2013). Expression of human interferon-gamma gene in human tissue culture cells. Biotechnology and Biotechnological Equipment, 27(1), 3573-3576. DOI: [DOI:10.5504/BBEQ.2012.0128]

49. Marciano, B.E., Wesley, R., De Carlo, E.S., Anderson, V.L., Barnhart, L.A., Darnell, D., et al. (2004). Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clinical Infectious Diseases, 39(5), 692-699. DOI: [DOI:10.1086/422993]

50. Martínez-Planas, A., Baquero-Artigao, F., Santiago, B., Fortuny, C., Méndez-Echevarría, A., Del Rosal, T., et al. (2021). Interferon-gamma release assays differentiate between mycobacterium avium complex and tuberculous lymphadenitis in children. The Journal of Pediatrics, 236, 211-218. DOI: [DOI:10.1016/j.jpeds.2021.05.008]

51. Martínez-Sabadell, A., Arenas, E.J., & Arribas, J. (2022). IFN-γ signaling in natural and therapy-induced antitumor responses IFN-γ signaling in antitumor responses. Clinical Cancer Research, 28(7), 1243-1249. DOI: [DOI:10.1158/1078-0432.CCR-21-3226]

52. Mikulecký, P., Zahradník, J., Kolenko, P., Černý, J., Charnavets, T., Kolárová, L., et al. (2016). Crystal structure of human interferon-γ receptor 2 reveals the structural basis for receptor specificity. Acta Crystallographica Section D: Structural Biology, 72(9), 1017-1025. DOI: [DOI:10.1107/S2059798316012237]

53. Milanes-Virelles, M., Garcia-Garcia, I., Santos-Herrera, Y., Valdes-Quintana, M., Valenzuela-Silva, C.M., Jimenez-Madrigal, G., et al. (2008). Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebocontrolled study. BMC Infectious Diseases, 8, 17. DOI: [DOI:10.1186/1471-2334-8-17]

54. Miller, C.H., Maher, S.G., & Young, H.A. (2009). Clinical use of interferon‐γ. Annals of the New York Academy of Science Journal, 1182(1), 69-79. DOI: [DOI:10.1111/j.1749-6632.2009.05069.x]

55. Mironova, R., Niwa, T., Dimitrova, R., Boyanova, M., & Ivanov, I. (2003). Glycation and post-translational processing of human interferon-γ expressed in Escherichia coli. Journal of Biological Chemistry, 278(51), 51068-51074. DOI: [DOI:10.1074/jbc.M307470200]

56. Mori, M., Zhang, G.H., Kaido, M., Okuno, T., & Furusawa, I. (1993). Efficient production of human gamma interferon in tobacco protoplasts by genetically engineered brome mosaic virus RNAs. Journal of General Virology, 74(7), 1255-1260. DOI: [DOI:10.1099/0022-1317-74-7-1255]

57. Moss, R.B., Hsu, Y.P., & Olds, L. (2009). Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clinical and Experimental Immunology, 120(3), 518-525. DOI: [DOI:10.1046/j.1365-2249.2000.01232.x]

58. Moss, R.B., Mayer-Hamblett, N., Wagener, J., Daines, C., Hale, K., Ahrens, R., et al. (2004). Randomized, double-blind, placebocontrolled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatric Pulmonology, 39(3), 209-218. DOI: [DOI:10.1002/ppul.20152]

59. Muir, A.J., Sylvestre, P.B., & Rockey, D.C. (2006). Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. Journal of Viral Hepatitis, 13(5), 322-328. DOI: [DOI:10.1111/j.1365-2893.2005.00689.x]

60. Myasnikov, A.L., Berns, S.A., Talyzin, P.A., & Ershov, F.I. (2021). Interferon gamma in the treatment of patients with moderate COVID-19. Problems of Virology, 66, 47-54. DOI: [DOI:10.36233/0507-4088-24]

61. Nacheva, G., Todorova, K., Boyanova, M., Berzal-Herranz, A., Karshikoff, A., & Ivanov, I. (2003). Human interferon gamma: significance of the C-terminal flexible domain for its biological activity. Archives of Biochemistry and Biophysics, 413(1), 91-98. DOI: [DOI:10.1016/S0003-9861(03)00113-9]

62. Nakajima, T., Tsunoda, S., Nakada, S., Nagata, S., & Oda, K. (1992). Hyperproduction of human interferon γ by rat cells maintained in low-serum medium using the fibronectin gene promoter. Journal of Biochemistry, 112(5), 590-597. DOI: [DOI:10.1093/oxfordjournals.jbchem.a123945]

63. Nassaj Hosseini, S.M., Shams-Bakhsh, M., Salamanian, A.H., & Yeh, S.D. (2012). Expression and purification of human interferon gamma using a plant viral vector. Progress in Biological Sciences, 2(2), 104-115. DOI: 10.22059/pbs.2013.2715

64. Ni, L., & Lu, J. (2018). Interferon gamma in cancer immunotherapy. Cancer Medicine, 7(9), 4509-4516. DOI: [DOI:10.1002/cam4.1700]

65. Okay, G., Koc, M.M., Guler, E.M., Yabaci, A., Kocyigit, A., & Akkoyunlu, Y. (2020). The effect of antiretroviral therapy on IL-6, IL-1β, TNF-α, IFN-γ levels and their relationship with HIV-RNA and CD4+ T cells in HIV patients. Current HIV Research, 18(5), 354-361. DOI: [DOI:10.2174/1570162X18666200712174642]

66. Pappas, P., Bustamante, B., Ticona, E., Hamill, R.J., Johnson, P.C., Reboli, A., et al. (2004). Recombinant interferon-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. The Journal of Infectious Diseases, 189(12), 2185-2191. DOI: [DOI:10.1086/420829]

67. Premzl, M. (2020). Comparative genomic analysis of eutherian interferon genes. Genome, 112(6), 4749-4759. DOI: [DOI:10.1016/j.ygeno.2020.08.029]

68. Raghu, G., Brown, K.K., Bradford, W.Z., Starko, K., Noble, P.W., Schwartz, D.A., et al. (2004). A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine, 350(2), 125-133. DOI: 10.1056/NEJMoa030511 [DOI:10.1056/NEJMoa030511]

69. Raghu, G. (2017). Idiopathic pulmonary fibrosis: Lessons from clinical trials over the past 25 years. European Respiratory Journal, 50(4), 1701209. DOI: 10.1183/13993003.01209-2017 [DOI:10.1183/13993003.01209-2017]

70. Razaghi, A., Owens, L., & Heimann, K. (2016a). Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. Journal of Biotechnology, 240, 48-60. DOI: [DOI:10.1016/j.jbiotec.2016.10.022]

71. Razaghi, A., Tan, E., Lua, L., Owens, L., Karthikeyan, O.P., & Heimann, K. (2016b). Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma? Biologicals, 45, 52-60. DOI: [DOI:10.1016/j.biologicals.2016.09.015]

72. Razmi, S., Jalali Javaran, M., Bagheri, A., Honari, H., & Soleimani Zadeh, M. (2019). Expression of human interferon gamma in tobacco chloroplasts. Romanian Biotechnological Letters, 24(2), 208-215. DOI: 10.25083/rbl/24.2/208.215 [DOI:10.25083/rbl/24.2/208.215]

73. Riddell, L.A., Pinching, A.J., Hill, S., Ng, T.T., Arbe, E., Lapham, G.P., et al. (2001). A phase III study of recombinant human interferon gamma to prevent opportunistic infections inadvanced HIV disease. AIDS Research and Human Retroviruses, 17(9), 789-797. DOI: 10.1089/088922201750251981 [DOI:10.1089/088922201750251981]

74. Rodrigues, M.E., Costa, A.R., Henriques, M., Cunnah, P., Melton, D.W., Azeredo, J., et al. (2013). Advances and drawbacks of the adaptation to serum-free culture of CHO-K1 cells for monoclonal antibody production. Applied Biochemistry and Biotechnology, 169(4), 1279-1291. DOI: [DOI:10.1007/s12010-012-0068-z]

75. Rojas Contreras, J.A., Pedraza-Reyes, M., Ordonez, L.G., Estrada, N.U., Barba de la Rosa, A.P., & De Leon-Rodriguez, A. 2010. Replicative and integrative plasmids for production of human interferon gamma in Bacillus subtilis. Plasmid, 64(3), 170-176. DOI: [DOI:10.1016/j.plasmid.2010.07.003]

76. Sandborn, W.J., Rutgeerts, P., Colombel, J-F., Ghosh, S., Petryka, R., Sands, B.E., et al. (2017). Eldelumab [anti-interferon-γ-inducible protein-10 antibody] induction therapy for active Crohn's Disease: a randomised, double-blind, placebo-controlled phase IIa study. Journal of Crohn's and Colitis, 11(7), 811-819. DOI: [DOI:10.1093/ecco-jcc/jjx005]

77. Sareneva, T., Cantell, K., Pyhälä, L., Pirhonen, J., & Julkunen, I. (1993). Effect of carbohydrates on the pharmacokinetics of human interferon-γ. Journal of Interferon and Cytokine Research, 13(4), 267-269. DOI: 10.1089/jir.1993.13.267 [DOI:10.1089/jir.1993.13.267]

78. Sareneva, T., Mortz, E., Tölö, H., Roepstorff, P., & Julkunen, I. (1996). Biosynthesis and N‐glycosylation of human interferon‐γ: Asn25 and Asn97 differ markedly in how efficiently they are glycosylated and in their oligosaccharide composition. European Journal of Biochemistry, 242(2), 191-200. DOI: 10.1111/j.1432-1033.1996.0191r.x [DOI:10.1111/j.1432-1033.1996.0191r.x]

79. Selman, M., Thannickal, V.J., Pardo, A., Zisman, D.A., Martinez, F.J., & Lynch, J.P. (2004). Idiopathic pulmonary fibrosis: Pathogenesis and therapeutic approaches. Drugs, 64, 405-430. DOI: [DOI:10.2165/00003495-200464040-00005]

80. Sigidin, Y.A., Loukina, G.V., Skurkovich, B., & Skurkovich, S. (2001). Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 30(4), 203-207. DOI: [DOI:10.1080/030097401316909530]

81. Skurkovich, B., & Skurkovich, S. (2003). Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Current Opinion in Molecular Therapeutics, 5(1), 52-57.

82. Talaat, R.M., Elsharnoby, S., Abdelkhalek, M.S., El-Shenawy, S.Z., & Elmasry, S. (2022). The impact of interferon-γ (IFN-γ) and IFN-γ-inducible protein 10 (IP-10) genes' polymorphism on risk of Hepatitis C Virus-related liver cirrhosis. Immunological Investigations, 51(3), 688-704. DOI: [DOI:10.1080/08820139.2020.1869251]

83. Tsai, M., Thauland, T.J., Huang, A.Y., Bun, C., Fitzwater, S., Krogstad, P., et al. (2020). Disseminated coccidioidomycosis treated with interferon-γ and dupilumab. The New England Journal of Medicine, 382(24), 2337-2343. DOI: 10.1056/NEJMoa2000024 [DOI:10.1056/NEJMoa2000024]

84. Wang, D., Ren, H., Xu, J.W., Sun, P.D., & Fang, X.D. (2014). Expression, purification and characterization of human interferon-γ in Pichia pastoris. Molecular Medicine Reports, 9(2), 715-719. DOI: [DOI:10.3892/mmr.2013.1812]

85. Wirusanti, N.I., Baldridge, M.T., & Harris, V.C. (2022). Microbiota regulation of viral infections through interferon signaling. Trends in Microbiology, 30(8), 778-792. DOI: [DOI:10.1016/j.tim.2022.01.007]

86. Wu, Y., Zhao, D., Song, L., & Xu, W. (2009). Heterologous expression of synthetic chicken IFN-γ in transgenic tobacco plants. Biologia, 64(6), 1115-1122. DOI: [DOI:10.2478/s11756-009-0203-7]

87. Xie, F.J., Zhao, P., Zhang, Y.P., Liu, F.Y., Nie, X.L., Zhu, Y.H., et al. (2013). Adenovirus‐mediated Interferon‐γ gene therapy induced human pancreatic carcinoma capan‐2 cell apoptosis in vitro and in vivo. The Anatomical Record, 296(4), 604-610. DOI: [DOI:10.1002/ar.22661]

88. Yaghtin, A., Jalali Javaran, M., & Karimzadeh, G. (2012). Transfer of human interferon γ-oleosin genes to safflower (Carthamus tinctorius L.). Genetic Engineering and Biosafety Journal, 1(2), 93-102. URL: http://gebsj.ir/article-1-231-fa.html

89. Yang, Y., Wang, H.J., Hu, W.L., Bai, G.N., & Hua, C.Z. (2022). Diagnostic value of interferon-gamma release assays for tuberculosis in the immunocompromised population. Diagnostics, 12(2), 453. DOI: [DOI:10.3390/diagnostics12020453]

90. Zhang, S., Li, X., Tian, Y., Chen, H., Liang, D., Chen, K., et al. (2022). Assay for interferon gamma release as a novel marker in pediatric patients with systemic lupus erythematosus. Research Square. DOI: https://doi.org/10.21203/rs.3.rs-2272370/v1 [DOI:10.21203/rs.3.rs-2272370/v1.]

91. Zhao, P., Zhu, Y.H., Wu, J.X., Liu, R.Y., Zhu, X.Y., Xiao, X., et al. (2007). Adenovirus-mediated delivery of human IFNγ gene inhibits prostate cancer growth. Life Science, 81(9), 695-701. DOI: [DOI:10.1016/j.lfs.2007.05.028]

92. Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.H. (1999). A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine, 341(17), 1264-1269. DOI: 10.1056/NEJM199910213411703 [DOI:10.1056/NEJM199910213411703]

93. Zuo, Y., Wu, J., Xu, Z., Yang, S., Yan, H., Tan, L., et al. (2011). Minicircle-oriP-IFNγ: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS One, 6(5), 1-12. DOI: [DOI:10.1371/journal.pone.0019407]

94. Zwerling, A., Van Den Hof, S., Scholten, J., Cobelens, F., Menzies, D., & Pai, M. (2012). Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax, 67(1), 62-70. DOI: http://dx.doi.org/10.1136/thx.2010.143180 [DOI:10.1136/thx.2010.143180]